The maker of a new category of small, wearable insulin patch pumps—designed to comfortably provide therapy to people with ...

Medtronic has agreed to not only expand the size of its board of directors, but to also task it with taking a closer look at ...

Partnering with VantAI could give Halda a source of target-effector pairs for its next wave of prospects. The deal could be ...

CSL is laying off up to 15% of its workforce as the Australian pharma looks to cut R&D costs and spin out its vaccine ...

Opthea’s options may be shrinking as the eye disease biotech comes to terms with a pair of phase 3 failures, but the company ...

China’s RemeGen has sold certain Asia rights to its phase 3-stage eye disease drug to Japan’s Santen Pharmaceutical for 250 ...

Gene therapy biotech Kriya Therapeutics has secured $313 million in a new series fundraise. | Gene therapy biotech Kriya ...

Delays from the Food and Drug Administration continue to pile up, with Maryland-based Regenxbio the latest to report the review of one of its assets ...

PTC Therapeutics has long been trying to workshop its vatiquinone into a marketable treatment for Friedreich's ataxia (FA) after a phase 3 fail in 2023. | Despite missing its primary endpoint in a ...

After years of striking acquisitions to build up its site network, Headlands Research has now been bought itself.  | After ...

Genentech is continuing its summer of downsizing and cost-cutting, this time with plans to terminate a cell therapy deal ...

In an update to their guidelines for treating high blood pressure, a group of cardiovascular medical societies has included a ...